Look back at pharma news in week to July 13

mergers-acquisitions-big

Deal-making news last week included Benitec Biopharma’s collaboration with Axovant Sciences on rare disease drug BB-301, which sent the Australian firm’s shares more than doubling. On the M&A front, BioCryst’s merger with Idera was resisted by shareholders. Company news included disappointment for Regulus Therapeutics when it paused clinical studies and slashed its work force. Also attracting attention was Pfizer’s announcement to defer planned drug price hikes and Pfizer’s decision to reorganize its business.

Not developing your gene therapy? Call Axovant

If you run a small-cap biotech company and have a gene therapy asset languishing in your patent portfolio then this could be your lucky day: Axovant is buying, commented EP Vantage, the editorial arm of the Evaluate group.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical